This 60-minute live and virtual symposium will include expert faculty engaged in a fast-paced, interactive discussion of prescription digital therapeutics (PDTs). Topics covered will include the definition and core concepts of PDTs; current evidence in clinical trials and PDTs on the horizon; and the role of PDTs in therapy and their potential impact in psychiatric disorders.
This satellite symposium held in conjunction with Psychiatry Update 2024, requires separate registration to attend in person. Registration for the virtual component is complementary and independently organized. This symposium is not an official part of the Psychiatry Update 2024 conference. For more details about in-person attendance, please visit www.psychiatryupdate.com
MODERATOR
Christoph U. Correll, MD
Professor of Psychiatry and Molecular Medicine
The Donald and Barbara Zucker School of Medicine at Hofstra/Northwell
Hempstead, New York, United States
Professor and Chair
Department of Child and Adolescent Psychiatry
Charité - University Medicine
Berlin, Germany
PANELIST
Leslie Citrome, MD, MPH
Clinical Professor
Psychiatry and Behavioral Sciences
New York Medical College
Valhalla, New York, United States
PANELIST
Lisa A. Marsch, PhD
Andrew G. Wallace Professor
Director, Center for Technology and Behavioral Health
Director, Northeast Node National Drug Abuse Treatment Clinical Trials Network
Geisel School of Medicine
Dartmouth College
Hanover, New Hampshire, United States
9:25 am
9:30 am
9:40 am
10:00 am
10:20 am
The goal of this activity is for learners to acquire comprehensive knowledge of Precision Digital Therapeutics (PDTs) and understand the fundamental definition and core concepts of PDTs, including their future applications. Additionally, learners will critically review current evidence and ongoing clinical trials, elucidating the efficacy of PDTs in addressing various mental health conditions.
This activity is intended for psychiatrists, primary care physicians, nurse practitioners, and physician assistants involved in the care of patients with psychiatric conditions.
Upon completion of this activity, participants will:
Have increased knowledge regarding the
Demonstrate greater confidence in their ability to
In support of improving patient care, Medscape, LLC is jointly accredited with commendation by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Medscape, LLC designates this live activity for a maximum of 1.0 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Awarded 1.0 contact hour(s) of nursing continuing professional development for RNs and APNs.